NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics is well-positioned for future growth, with a strong financial performance in Q1 2026. The company's 11.1% Y/Y revenue growth and 8.1% organic growth are both positive signs, as well as their ability to beat consensus estimates. This growth is driven by a combination of increased volumes, higher average selling prices, and new product launches, specifically in the NGS segment. Management's confidence in continued 20%+ NGS growth, along with a strong position in the community channel and plans to expand their sales force, further support a positive outlook for the company. Additionally, the potential for margin expansion and favorable outcomes from patent litigation are potential upside drivers, making NeoGenomics an attractive stock in the oncology diagnostic testing space.

NeoGenomics is facing challenges with its ~$342M convertible debt due in 2028 and may need to raise additional funds through an equity offering, which could dilute shareholders. Additionally, the delayed launch of their whole genome-based hematalogical malignancy profiling test, combined with a lack of disclosure on their exposure to this market, raises concerns about their overall growth potential. While the company is expecting positive free cash flow in 2026, their margin guidance and revenue growth may be impacted by the costs associated with this new test.